HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Grant

Date/time Interval

  • January 1, 2017 - November 30, 2020
  • Total Award Amount

  • 1523723.00
  • Direct Costs

  • 1036547.00
  • Sponsor Award Id

  • PO17001904
  • Contributor

  • Edgar Overton   Principal Investigator  
  • Michael Saag M.D.   Investigator  
  • Paul Goepfert M.D.   Investigator  
  • Sonya Heath   Investigator